Articles

MuSK and ALS

Multi-center team finds that treatment with a genetically engineered stimulatory agonist antibody to MuSK can preserve nerve-muscle synapses in mouse models of ALS
Written byKelsey Kaustinen
| 3 min read

WASHINGTON, D.C.—Amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, is a neurodegenerative disease typified by the loss of motor neurons in the brain and spinal cord, eventually resulting in the loss of voluntary muscle movement, paralysis and death. While progress has been made in understanding the disease, there is still no cure, nor treatments to slow or reverse disease progression.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.